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Background: The role of estrogen and progesterone in ovarian carcinogenesis and the growth and survival of ovarian
cancer cells is controversial. In this study, we tested the effects of various concentrations of estrogen and progesterone
on the survival of an ovarian cancer cell line.
Methods: The ovarian adenocarcinoma cell line, OC-117-VGH, is deficient in the following receptors: estrogen receptor
(ER)_, ER`, and progesterone receptor (PR). Serial concentrations of estrogen and progesterone were used to evaluate
the effects of estrogen and progesterone on the survival of ovarian cancer cells. The apoptosis-related genes Bcl-
2 and Bax were used to check the possible mechanism of an estrogen or progesterone effect on survival of the
cancer cell line.
Results: Estrogen 0.01–1.0 μM and progesterone 0.1–10.0 μM affected cell survival. As predicted, progesterone
successfully downregulated anti-apoptotic Bcl-2 expression, and dose-dependently suppressed Bcl-2 expression
in tumor cells. Paradoxically, estrogen showed the same effects. In addition, both hormones downregulated pro-
apoptotic Bax expression. The net effect confirmed the role of downregulated Bcl-2 in reducing the survival of
ovarian cancer cells.
Conclusion: Based on the findings of decreased survival and/or growth in OC-117-VGH ovarian adenocarcinoma
cells treated with either estrogen or progesterone, we suspect that both hormones act effectively against ER-negative
and PR-negative ovarian cancer cells. These findings should lead to a reassessment of hormone therapy for ovarian
cancers. [J Chin Med Assoc 2005;68(8):360–367]
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Introduction
Ovarian cancer is a malignant disease of worldwide
importance, and is the leading cause of cancer mortality
in female patients, not only in the US, but also in
Taiwan.1,2 The initial treatment for ovarian cancer is
surgical resection of the primary tumor, followed by
postoperative adjuvant chemotherapy or possible
radiation.3 Ovarian tumors showing resistance to
chemotherapy usually suggest a poor prognosis.4 The
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causes of ovarian epithelial cancer have not yet been
clearly defined, but recent epidemiologic studies
reported that estrogen and/or progesterone may
promote ovarian tumor progression in postmenopausal
women.5 In addition, the Women’s Health Initiative
(WHI) randomized trial expressed concerns about a
possible association between gynecologic malignancies
and postmenopausal hormone therapy.6 There is also
growing experimental evidence that estrogen and/or
progesterone may play important roles in ovarian
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carcinogenesis, including the control of cellular
differentiation and growth, and apoptosis of ovarian
cancer cells.7 However, the nature of such roles is
controversial.4,5,7
Apoptosis, or programmed cell death, is a vital
physiologic process for the elimination of damaged
or unwanted cells.8,9 A hallmark of tumorigenesis is
the outgrowth of a clonal population of cells that
are insensitive to certain apoptotic signals. Various
apoptotic stimuli signal through Bcl-2 family proteins
in the core apoptotic machinery, and Bax is an essential
factor in apoptosis initiation.10
In the present study, we used an established ovarian
adenocarcinoma cell line, OC-117-VGH, which is
negative for estrogen receptor (ER)_, ER` and
progesterone receptor (PR), to investigate the role of
estrogen or progesterone in tumor cell growth using
the CellTiter 96® AQueous (CTAQ) Assay system
(Promega US, Madison, WI, USA). We further
evaluated regulators of tumor survival during estrogen
or progesterone treatment. The selected candidate
was the Bcl-2 gene family, which has been widely
considered to regulate cell death; thus, we also assessed
changes in the expression of Bcl-2 and Bax.
Methods
Cell line
An ovarian adenocarcinoma cell line, OC-117-VGH,
was initiated from a clear cell adenocarcinoma that had
been removed from a 56-year-old woman who
underwent debulking surgery for surgicopathological
stage IIIC ovarian cancer in 1997. The OC-117-VGH
cell culture was late-passage (> 80) negative for ER_,
ER` and PR. We used the polymerase chain reaction
(PCR) method7 to prove the deficiencies in ER_, ER`
and PR in this cell line. The ER_ (NM_000125) was
amplified using the forward primer 5’–AGG–TGC–
CCT–ACT–ACC–TGG–AGA–AC–3’, and the reverse
primer 5’–GGT–GGC–TGG–ACA–CAT–ATA–
GTC–GTT–3’ (amplicon length, 293 base pairs [bp]).
The ER` (NM_001437) was amplified using the
forward primer 5’–GTT–TAG–TGG–TCC–ATC–
GCC–AGT–TAT–3’, and the reverse primer 5’–CTT–
ACA–TCC–TTC–ACA–CGA–CCA–GAC–3’
(amplicon length, 248 bp). The PR (NM_000926)
was amplified using the forward primer 5’–GAT–
TCA–GAA–GCC–AGC–CAG–AG–3’, and the reverse
primer 5’–TGC–CTC–TCG–CCT–AGT–TGA–TT–
3’ (amplicon length, 533 bp).
Human ovarian cancer cells (SKOV-3; American
Type Culture Collection, Manassas, VA, USA),11,12
which are positive for ER_ but negative for ER` and
PR, were used as control.
Cell culture
OC-117-VGH cells were grown in a culture medium
containing a 1:1 mixture of Dulbecco’s modified
Eagle’s essential medium (Gibco BRL, Grand Island,
NY, USA) and nutrient mix F-12 medium (Invitrogen
Corp, Carlsbad, CA, USA), supplemented with 10%
heat-inactivated fetal bovine serum (FBS; HyClone,
Logan, UT, USA), penicillin 100 U/mL, streptomycin
100 μg/mL, and amphotericin B 2.5 μg/mL. Cells
were incubated at 37°C with 5% CO2, and at more
than 95% humidity. SKOV-3 cells were maintained in
culture at 37°C/5% CO2 using Iscove’s modified
Dulbecco’s medium (HyClone) supplemented with
glutamine and 10% heat-inactivated FBS (HyClone).
Media were changed twice a week, and cells were
subcultured weekly by detachment with 2.5 mg/mL
trypsin/ethylenediamine tetra-acetic acid 0.02% in
Dulbecco’s phosphate-buffered saline (PBS) solution
(Gibco BRL). Cells were maintained and subcultured
every 2–4 weeks and split at a 1:2 to 1:4 ratio prepared
for subsequent studies.
Estrogen and progesterone treatment
Aliquots (100 μL) containing 1 × 106 cells/mL were
dispensed into a 96-well plate (Corning Inc, Big Flats,
NY, USA). Triplicate cultures for each test were
incubated for 24 hours at 37°C, then 100 μL of
different concentrations of estrogen and progesterone
were added. Estrogen and progesterone were added
separately to final concentrations of 0.01–1.0 μM and
0.1–10.0 μM, respectively, prepared in a serum-free
medium. A serum-free culture medium was used for
the control. Cells were treated with estrogen 0.01–
1.0 μM and progesterone 0.1–10.0 μM for 16, 24, 48
and 72 hours at 37°C, with 5% CO2 and more than
95% humidity.
Cell survival assay
Cell proliferation assays were examined using the
CellTiter 96® AQueous Assay system.
13 At the last 4-hour
segment of estrogen and progesterone treatment, we
added 20 mL per well of CTAQ. At the end, we read
the plate with a microplate reader (Multiscan®,
Labsystems, Helsinki, Finland) at an optical density
(OD) of 490 nm.
Results were expressed as percent of cell survival
after estrogen and progesterone treatment in culture
media versus controls. Estrogen- and progesterone-
treated survival rates at each concentration were
calculated as follows:
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ELISA detection
Bcl-2 and Bax expression were determined by an
enzyme-linked immunosorbent assay (ELISA) of the
estrogen- and progesterone-treated cells. After 24, 48
and 72 hours of treatment, cells were washed with PBS
and fixed in 75% ethanol for 10 minutes. This was
followed by incubation with acetic acid 0.03% in PBS
for 30 minutes. The cells were then incubated with
rabbit anti-Bcl-2 or Bax primary antibodies
(DakoCytomation California Inc, Carpenteria, CA,
Survival rate Absorbance of treated wells – mean absorbance of background
relative to = × 100%
control (%) Absorbance of control wells – mean absorbance of background
The expression of Bcl-2 and Bax at each condition was calculated as follows:
Percentage Absorbance of treated wells – mean absorbance of background
relative to = × 100%
control (%) Absorbance of control wells – mean absorbance of background
RNA purification and checking of the Bcl-2 and
Bax-_ genes using RT-PCR
We used the TRIzol® kit (Gibco BRL) to purify the
RNA of ovarian cancer cells. We added 1 mL of
TRIzol® solution to the drug-treated ovarian cancer
cells, after centrifugation at 12,000g at 4°C for 30
minutes, collected the upper layer, and added
isopropenol, after another centrifugation at 12,000g
at 4°C for 30 minutes, and then washed the RNA twice
with 70% alcohol.
We used the SuperScript® First-Strand Synthesis
System (Gibco BRL) reverse transcriptase-polymerase
chain reaction (RT-PCR) of RNA to cDNA, following
the manufacturer’s protocol, by incubating 1 μg of
total RNA with oligo-d(T)12-18 (Invitrogen,
Carlsbad, CA, USA) as the initiation primer in a final
reaction volume of 20 μL, as described elsewhere.14–16
The primers used for detecting genes by the RT-PCR
method were as follows: the Bcl-2 gene was amplified
using the forward primer 5’–GGT–GCC–ATT–ATT–
ATG–CAG–CCA–G–3’ (GenBank® accession number
M14745; nucleotides 722–743), and the reverse primer
5’–CCT–ATC–TGG–GCC–ACA–AGT–GAA–G–3’
(GenBank® accession number M14745; nucleotides
875–899) (amplicon length, 178 bp).17 The Bax-_
gene was amplified using the forward primer 5’–ATG–
G A C – G G G – T C C – G G G – G A G – C A G – C – 3 ’
(GenBank® accession number L22473; nucleotides
1–22), and the reverse primer 5’–CGA–GTC–GAA–
GAA–CCA–CCT–GCG–T–3’ (GenBank® accession
USA; 1:200 dilution) for 60 minutes at 37°C. After
washing, the cells were then incubated with goat anti-
rabbit alkaline phosphatase-labeled secondary
antibodies (DakoCytomation California Inc; 1:500
dilution) for another 60 minutes at 37°C. Finally, the
cells were incubated with 7 mM of p-nitrophenyl
phosphate (Sigma-Aldrich Corp, St Louis, MO, USA)
in a sodium bicarbonate buffer 0.01 M, pH 10.0, for
30 minutes, and then read using Multiscan®
(Labsystems) at OD 410 nm.
number L22473; nucleotides 149–170) (amplicon
length, 170 bp).18 Expression of the glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) housekeeping gene
was used to determine the cDNA yield and to check for
possible contamination with genomic DNA. For this
purpose, an intron-sparing GAPDH-specific primer
(M17851) was designed: GAPHD forward primer,
5’–ATG–TTC–GTC–ATG–GGT–GTG–AAC–CA–3’
(nucleotides 421–443), and GAPDH reverse primer,
5’–TGG–CAG–GTT–TTT–CTA–GAC–GGC–AG–3’
(nucleotides 771–793) (amplicon length, 373 bp).19
Southern blotting
Southern blot hybridization was used to identify the
PCR-amplified cDNA fragment. The PCR-amplified
products were subjected to electrophoresis in 2%
agarose gels and transferred onto nylon membranes.
The DNA, linked to the nylon membrane by exposure
to ultraviolet light (254 nm) at 1.5 J/cm2, was
prehybridized for 4 hours at room temperature in 6 M
saline sodium citrate. cDNA probes 1–2 ng (above)
were labeled with digoxigenin. Probe cocktails labeled
with digoxigenin were used in the non-radioactive in
situ hybridization method.20
Statistical analysis
Statistical analysis of the data was performed with
Statistica version 5.1 (StatSoft Holdings Inc, Tulsa,
OK, USA) and SPSS version 12.0 (SPSS Inc, Chicago,
IL, USA). Every experiment was repeated 6 times.
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Experimental data were presented as mean ± standard
deviation, using Dunnet’s test. Statistical analysis was
performed by repeated analysis of variance (ANOVA),
with a post hoc test for between-group analysis. A p value
of less than 0.05 was considered statistically significant.
Results
Before we evaluated the effect of estrogen and
progesterone on the survival of the OC-117-VGH
ovarian adenocarcinoma cell line, we used PCR to
identify the absence of functional ER_, ER` and PR in
the cell line (data not shown). Then, we evaluated the
survival rate of the cell line treated with different
estrogen concentrations (0.01–1.0 μM). Paradoxically,
survival of cancer cells in this study was significantly
impaired with estrogen treatment. Even at the low
concentration of 0.01 μM, only 63.6 ± 6.7% of cancer
cells survived; this impaired survival seemed to depend
on estrogen concentration (p = 0.02). Furthermore,
the longer the exposure of the OC-117-VGH cell line
to estrogen, the greater the effect on cancer cell
survival, especially at the highest estrogen concentration
of 1.0 μM (p = 0.04); this suggested a time-dependent
effect for estrogen on cancer cell survival at higher
concentrations (Figure 1). By contrast, the various
concentrations of estrogen did not significantly affect
SKOV-3 cell growth (data not shown), which is in
agreement with a previous report.12 This SKOV-3 cell
growth study indirectly suggested that estrogen did
not cause cytotoxicity at any concentration.
We replaced estrogen with progesterone to evaluate
the effect of progesterone on ovarian cancer cells. As
predicted, progesterone showed similar but more
significant effects than estrogen. We found that the
survival of ovarian cancer cells was significantly impaired
during progesterone treatment, in both a dose-
dependent (p = 0.001) and exposure time-dependent
manner (p = 0.04; Figure 2), thus suggesting that
progesterone may be a protective factor against ovarian
cancers. A similar phenomenon was also noted in the
SKOV-3 cell line (data not shown), which is in
agreement with a previous report.11
To further dissect the mechanism of estrogen or
progesterone in the survival of OC-117-VGH cells,
we used an ELISA assay and RT-PCR to check levels
of the anti-apoptotic Bcl-2 protein and Bcl-2 mRNA
expression. In agreement with the cell survival study,
both protein and mRNA levels of Bcl-2 showed
downregulation during estrogen treatment (66.2%,
58.3% and 55.1% of mean values at the 24-, 48- and
72-hour assessments, respectively; p = 0.04). This
effect was more dramatic in the OC-117-VGH cells
treated with progesterone (74.7%, 58.1% and 40.6% of
mean values; p = 0.01). The downregulation of Bcl-2
was more significant with progesterone, because we
could clearly determine the time-dependent effect of
progesterone on Bcl-2 expression (Figure 3).
Since the balance between anti-apoptotic and pro-
apoptotic signals plays a crucial role in cell survival, we
further evaluated expression of the pro-apoptotic
marker Bax on OC-117-VGH cells during estrogen
and progesterone treatment, using both ELISA and
Figure 1. Survival rate of OC-117-VGH ovarian cancer cells
treated with estrogen (n = 6). Concentrations of estrogen in the
culture medium ranged from 0.01–1.0 μM. Impaired survival of
the ovarian cancer cell line was estrogen-dose-dependent and
estrogen-exposure time-dependent. SD = standard deviation.
Figure 2. Survival rate of OC-117-VGH ovarian cancer cells
treated with progesterone (n = 6). Concentrations of progesterone
in the culture medium ranged from 0.1–10.0 μM. Impaired
survival of the ovarian cancer cell line was progesterone-dose-
dependent and progesterone-exposure time-dependent. SD =
standard deviation.
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RT-PCR. Paradoxically, both Bax protein and mRNA
expression in OC-117-VGH cells were downregulated
during estrogen treatment (72.4%, 60.2% and 39.1%
of mean values at 24-, 48- and 72-hour assessments,
respectively; p = 0.01). This phenomenon was also
observed with OC-117-VGH cells treated with
progesterone (79.3%, 64.6%, and 35.4% of mean
values, respectively; p = 0.001; Figure 4).
Taken together, these results show that the OC-
117-VGH cell line was sensitive to both estrogen and
progesterone inhibition mediated through down-
regulation of the anti- and pro-apoptotic genes Bcl-2
and Bax. Although Bax was downregulated, it was
the net effect of Bcl-2 downregulation that impaired
OC-117-VGH survival.
Discussion
The common epithelial ovarian tumors appear to
arise from the ovarian surface epithelium, which is a
simple squamous-to-cuboidal mesothelium covering
the ovary.21 However, the exact mechanism of ovarian
tumorigenesis is not well known, although repeated
ovulation contributes to neoplastic transformation
of the ovarian surface epithelium, indicating that the
process of healing ruptured ovarian surface epithelium
may contribute to the disease.22 Therefore, it has
been suggested that endocrine and autocrine factors
may influence the occurrence of ovarian tumors in
women.4 The WHI study suggested the probability
of an increased risk of ovarian cancer associated with
long-term use of hormone replacement therapy
(HRT) with estrogen and progesterone.6 However,
this disagreed with other reports of an unchanged23,24
or reduced risk of ovarian cancer.25,26 Intriguingly,
the Heart and Estrogen/progestin Replacement Study
(HERS) II, a randomized trial of postmenopausal
women, recently reported no difference in the
incidence of ovarian cancer between an HRT and
placebo group.27
Conflicting results from various studies and clinical
trials may come from differences in methodology and
the existence of uncontrolled confounding factors.
Accumulation of evidence has long suggested estrogens
as causative factors in ovarian cancer.21,28–30 For instance,
ovarian tissue estrogen levels are at least 100-fold
higher than circulating levels, and levels are even
higher in the follicular fluid of ovulatory follicles. Syed
et al31 also reported that both estradiol-17` and estrone
stimulate growth of normal and malignant ovarian
surface epithelium cells mediated through ERs.
Importantly, estradiol-17` and estrone are of equal
potency in stimulating growth in ovarian surface
epithelium cells, although it is well known that estrone
is a much less potent estrogen than estradiol-17`.
Figure 4. Bax expression in OC-117-VGH ovarian cancer cells
treated with estrogen or progesterone (n = 6). The estrogen
concentration was 0.1 μM, whereas that of progesterone was
1.0 μM. Downregulation of Bax expression was noted with
estrogen and progesterone treatment. Southern blot hybridization
showed the consistent finding of time-dependent decreased
dosimetry density. bp = base pairs; GAPDH = glyceraldehyde-3-
phosphate dehydrogenase; SD = standard deviation.
Figure 3. Bcl-2 expression in OC-117-VGH ovarian cancer cells
treated with estrogen or progesterone (n = 6). The estrogen
concentration was 0.1 μM, whereas that of progesterone was
1.0 μM. Downregulation of Bcl-2 expression was noted with
estrogen and progesterone treatment. Southern blot hybridization
showed the consistent finding of time-dependent decreased
dosimetry density. bp = base pairs; GAPDH = glyceraldehyde-3-
phosphate dehydrogenase; SD = standard deviation.
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In addition, the mitogenic effects of estrogens on
ovarian surface epithelium cells are mediated through
activation of the interleukin-6/signal transducer and
activator of transcription-3 (STAT-3) signaling
pathway, and ovarian cancer cells express high levels of
constitutively activated STAT-3, a known transforming
cellular molecule.32
The mechanism of estrogen action is associated
with upregulation of the Bcl-2 gene at mRNA and
protein levels, and this suggests a role for estrogen in
ovarian tumorigenesis by preventing apoptosis in
tumorigenic ovarian surface epithelium cells.21
However, while the use of estrogen-based oral
contraceptives (high-dosage estrogen) is known to
reduce the risk of ovarian cancer, the ER_-positive cell
line SKOV-3 fails to respond to estrogen stimulation,12
as noted in this study. Furthermore, ER` is reported
to function as an important regulator of proliferation
and motility of ovarian cancer and to have a pro-
apoptotic role.33 The loss of ER` expression may thus
be an important event leading to the development of
ovarian cancer.34 Lau et al35 demonstrated expression
of ER_, ER` and PR mRNA in primary cultures of
normal ovarian surface epithelium cells. A moderate
reduction in ER_ mRNA expression, accompanied by
marked downregulation of PR expression, was noted
in ovarian cancer cell lines when compared with ovarian
surface epithelium cells.35
However, questions pertaining to the effects of
estrogen on ovarian carcinogenesis remain
unanswered.22 Our study agreed with data from the
above studies,33,34 showing ER` loss to be important
in ovarian carcinogenesis, since the OC-117-VGH
cell line was devoid of ER` function. Interestingly,
estrogen treatment in this cell line had a negative
effect on tumor survival, which disagrees with the
concept that estrogens are implicated as causative
factors in ovarian carcinogenesis,21,28–30 but seems to
support the study of Sapi et al,36 who showed that
estrogen may induce apoptosis and thus impair cell
survival; indeed, these investigators demonstrated
estrogen-induced upregulation of Fasl, an apoptotic
protein ligand, in ovary.36 Sex hormones may also
directly affect cell function and growth without
binding to their relevant hormone receptors; i.e.
these hormones can escape the classical pathway.4,37,38
Overall, in this study, the effect of estrogen on OC-
117-VGH survival and/or growth was not mediated
through ERs, since both ER_ and ER` are defective
in this cell line.
Progesterone, or the cellular response to
progesterone, appears to offer protection against
ovarian carcinogenesis.11,22,29 The SKOV-3 cell line,11,12
which is highly invasive, tumor-forming, and PR-
negative, was used as an experimental paradigm to
show that tumorigenesis is suppressed by progesterone
in immunocompromised nude mice inoculated
intraperitoneally with SKOV-3 cells.11 Of significance,
loss of heterozygosity at 11q23.3–24.3, which harbors
the PR gene locus, is commonly observed in ovarian
cancer specimens, and this genetic alteration is
associated with poor prognosis.39–41 Epidemiologic
data provide additional support that progesterone or
the response of ovarian surface epithelium cells to
steroids affords a protective role against ovarian cancer
development or progression.24 An increase in ovarian
cancer incidence was observed among women with
progesterone deficiency,42 and the protective effect of
pregnancy may be attributable to exposure of the
ovarian surface epithelium to high levels of progesterone
during pregnancy.43,44
Furthermore, women with a history of twin
pregnancies exhibit a lower risk of ovarian cancer,
possibly due to the higher levels of progesterone
found in the maternal circulation during twin rather
than singleton pregnancies.43,45 Indeed, it appears that
progesterone protects against the development of
common epithelial ovarian cancer.29 In this study, use
of the PR-negative cell line OC-117-VGH showed
that progesterone may play a protective role in epithelial
ovarian cancer, since progesterone successfully inhibited
cell growth and reduced survival of the cell line; these
findings were in complete agreement with previous
studies.11,22,42–45 However, progesterone activity may
also be mediated through a non-genomic effect or
non-PR-binding effect. Despite promising results from
the abovementioned studies, progestogens have been
of limited value in the treatment of ovarian cancer,
even though they have sometimes been used in patients
with advanced chemorefractory illness.46,47 Our
observations provide a conceptual basis for the
prophylactic and therapeutic use of progesterone in
individuals at high risk of ovarian carcinoma, and in
those diagnosed with early-stage disease. We further
hypothesize that high progesterone dosages may be
appropriate to achieve beneficial outcomes, since
adverse effects with progesterone in its natural form
are expected to be low.47
To clarify regulators of tumor survival during
estrogen and progesterone treatment, we further
studied the Bcl-2 gene family, members of which are
generally considered to be regulators of cell death,48,49
although the prognostic significance of Bcl-2 and/or
Bax remains controversial.50–52 Among pro- and anti-
apoptotic genes in the Bcl-2 family, Bax and Bcl-2
genes are dominant regulators of apoptosis. The ratio
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of Bcl-2 to Bax is critical in determining susceptibility
to apoptosis,49 and steroid hormones may regulate
pro- or anti-apoptotic genes in ovarian cancer
cells.21,29,53 In this study, estrogen (0.01–1.0 μM) and
progesterone (0.1–10.0 μM) decreased both Bax and
Bcl-2 protein, suggesting that a decrease in Bcl-2
protein plays a more important role that is unfavorable
to cell survival. The net effect of a decreased relative
ratio of Bcl-2 to Bax decreased survival and/or growth
in the OC-117-VGH cells.
Regarding study limitations, as the OC-117-VGH
cell line is deficient in ERs and PRs, the effects of
estrogen or progesterone on cell survival may not be
mediated through classical pathways (i.e. estrogen/
ER, and progesterone/PR); however, we did not
examine non-classical pathways (i.e. non-genomic
effects, or non-ER- or non-PR-binding effects) to
prove our observation that both estrogen and
progesterone decreased survival and/or growth in
OC-117-VGH cells. We did not quantify the
induction of apoptosis; indeed, DNA fragmentation
was measured using a cell-death detection ELISA
(Roche Molecular Biochemicals, Mannheim,
Germany) as previously reported.21 We also failed to
detect the typical morphologic characteristics of
apoptosis, such as compaction and margination of
chromosomes, nuclear fragments, and the formation
of apoptotic bodies. Therefore, it was difficult to
claim that the decreased survival and/or growth may
have been due to factors other than cytotoxicity,
although based on the above SKOV-3 study and
previous reports,7,12,21,32,33 such cytotoxicity was
unlikely. The decreased human cancer cell population
in vitro, as observed in this study, reflects a change in
the balance of cellular growth events and could
involve arrested cell proliferation, enhanced cell
death, or both;34 however, we did not classify which
one was predominant. Lastly, to detect changes in
Bcl-2 and Bax, we used a very sensitive RT-PCR
method, which might amplify small changes that
have no clinical significance.
In conclusion, the present study indicated that
both estrogen and progesterone impaired tumor
survival in the OC-117-VGH ovarian cancer cell line.
Although anti-apoptotic Bcl-2 and pro-apoptotic
Bax proteins were downregulated by estrogen and
progesterone, decreased Bcl-2 played the most
important role in contributing to the net effect of
reduced ovarian cancer cell survival. Our results also
confirm that estrogen and progesterone can be used
as chemopreventive agents against ovarian cancer,
especially against ER-negative and PR-negative
disease.
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